<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1196">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04484493</url>
  </required_header>
  <id_info>
    <org_study_id>RC 4-7-2020</org_study_id>
    <nct_id>NCT04484493</nct_id>
  </id_info>
  <brief_title>Corticosteroid Nasal Spray in COVID-19 Anosmia</brief_title>
  <official_title>Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the role of the topical corticosteroids nasal spray
      (mometasone furoate nasal spray) in improving anosmia in patients recovered from COVID-19
      infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study willbe submitted on patients who recently recovered from proven COVID-19 infection
      and complaining of anosmia or hyposmia.The proven COVID-19 infection will be relied on a
      positive real-time reverse transcription polymerase chain reaction (rRT-PCR) with samples
      obtained by a nasopharyngeal swab. The recovery is defined as 2 consecutives negative
      (rRT-PCR) samples.

      Complete medical history will be taken, and essential clinical assessment with appropriate
      protective measures will be performed in all patients.The patients in the study will be
      randomly divided into two groups: - Group I: -who will receive topical corticosteroid nasal
      spray (mometasone furoate nasal spray) beside olfactory training Group II: -who will not
      receive topical corticosteroid nasal spray but only olfactory training.

      As regards the assessment of smell,the patient will assess his smell sensation using familiar
      substances with distinctive odor. A jar of coffee, a branch of mint and garlic are some used
      substances. The patient will report the degree of anosmia subjectively with score on a scale
      from 0 to 10.The assessment of smell will be done initially after recovery/discharge, after 1
      week, 2 weeks and after 3 weeks for all patients. The duration of smell loss will be recorded
      from the onset of anosmia till full recovery of the sensation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2020</start_date>
  <completion_date type="Actual">September 6, 2020</completion_date>
  <primary_completion_date type="Actual">September 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of olfaction</measure>
    <time_frame>3 weeks</time_frame>
    <description>The patient will report the degree of anosmia subjectively with score on a scale from 0 to 10 (0 means total loss of smell and 10 refers to completely normal smell sensation).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Covid19</condition>
  <condition>Anosmia</condition>
  <arm_group>
    <arm_group_label>mometasone nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive topical corticosteroid nasal spray (mometasone furoate nasal spray) in appropriate dose of 2 puff in each nostril (100 µg once daily) beside olfactory training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive topical corticosteroid nasal spray but only olfactory training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate nasal spray</intervention_name>
    <description>dose of 2 puff in each nostril (100 µg once daily each nostril).</description>
    <arm_group_label>mometasone nasal spray</arm_group_label>
    <other_name>steroid nasal spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults 18 yrs or older patients

          -  confirmed case (+ve PCR),

          -  recovered/discharged (2 -ve PCR),

          -  suffered from sudden recent anosmia or hyposmia

        Exclusion Criteria:

          -  patients already on nasal steroid

          -  with previous chronic rhinological pathologies,

          -  patients on systemic steroid for previous systemic disease,

          -  anosmia improved before COVID19 recovery,

          -  pregnancy

          -  patients who will not complete the follow up period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdelrahman A Abdelalim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benha Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rasha A Elsayed, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Benha Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona A Elawady, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Benha Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdelhakim F Ghallab, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Benha Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman A Mohamady, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Benha Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Benha University Hospital, Faculty of Medicine</name>
      <address>
        <city>Banhā</city>
        <state>Qalubia</state>
        <zip>13512</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.europeanrhinologicsociety.org/?page_id=2143</url>
    <description>european rhinologic society</description>
  </link>
  <reference>
    <citation>Heilmann S, Just T, Göktas O, Hauswald B, Hüttenbrink KB, Hummel T. [Effects of systemic or topical administration of corticosteroids and vitamin B in patients with olfactory loss]. Laryngorhinootologie. 2004 Nov;83(11):729-34. German.</citation>
    <PMID>15538662</PMID>
  </reference>
  <reference>
    <citation>Hura N, Xie DX, Choby GW, Schlosser RJ, Orlov CP, Seal SM, Rowan NR. Treatment of post-viral olfactory dysfunction: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2020 Sep;10(9):1065-1086. doi: 10.1002/alr.22624. Epub 2020 Jun 25. Review.</citation>
    <PMID>32567798</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>September 6, 2020</last_update_submitted>
  <last_update_submitted_qc>September 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Abdelrahman Ahmed Abdelalim</investigator_full_name>
    <investigator_title>MD lecturer</investigator_title>
  </responsible_party>
  <keyword>covid19</keyword>
  <keyword>anosmia</keyword>
  <keyword>mometasone nasal spray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olfaction Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

